文献速递病毒性肝炎艾滋病与性传播感染

HCV/HIV共感染肝病病理生理:HCV治愈后是否终结?

Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure?
PubMed 文献 · J Infect Dis · 2020-01-01

该综述探讨直接抗病毒药物(DAA)时代HCV-HIV共感染者肝病病理生物学。DAA使持续病毒学应答率超95%并改善纤维化指标,但共感染者死亡风险和肝细胞癌严重程度仍高于HCV单感染,提示HIV本身独特通路持续促进肝病进展。

要点

  • DAA时代HCV-HIV共感染者持续病毒学应答率超95%,纤维化相关指标改善。
  • 共感染者死亡风险及肝细胞癌严重程度仍高于HCV单感染。
  • HIV本身诱导肝损伤的纤维化通路是诊断和治疗新靶点。

核心结论

  • HCV治愈后共感染者肝病风险仍高于单感染,HIV相关纤维化通路持续存在。

研究设计与样本

  • 综述,回顾DAA时代HCV-HIV共感染者肝病病理生物学及HIV诱导肝损伤机制。

主要发现

  • 共感染者肝损伤进展快于HCV单感染。
  • DAA使持续病毒学应答率超95%,纤维化相关参数改善。
  • 共感染者死亡风险更高,肝细胞癌更严重。

临床怎么用

  • 肝病是HIV阳性患者非AIDS相关死亡主因之一,需重视HCV治愈后的肝病监测。
  • 理解HIV相关纤维化通路有助于开发新诊断和治疗策略以延缓或逆转肝病进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HCV-HIV coinfected patients exhibit rapid progression of liver damage relative to HCV monoinfected patients. The availability of new directly acting antiviral agents has dramatically improved outcomes for coinfected patients as sustained virologic response rates now exceed 95% and fibrosis-related parameters are improved. Nevertheless, coinfected patients still have a higher mortality risk and more severe hepatocellular carcinoma compared to HCV monoinfected patients, implying the existence of pathways unique to people living with HIV that continue to promote accelerated liver disease. In this article, we review the pathobiology of liver disease in HCV-HIV coinfected patients in the directly acting antiviral era and explore the mechanisms through which HIV itself induces liver damage. Since liver disease is one of the leading causes of non-AIDS-related mortality in HIV-positive patients, enhancing our understanding of HIV-associated fibrotic pathways will remain important for new diagnostic and therapeutic strategies to slow or reverse liver disease progression, even after HCV cure.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jeyarajan AJ, Chung RT. Insights Into the Pathophysiology of Liver Disease in HCV/HIV: Does it End With HCV Cure? J Infect Dis. 2020. PMID: 33245355. doi:10.1093/infdis/jiaa279

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。